Ali Faraz 4

What Happened

• Ali Faraz, CEO of Tenaya Therapeutics (TNYA), received equity awards on February 3, 2026: 158,600 restricted stock units (RSUs) granted (acquired at $0) and a derivative award covering 952,250 shares (an option/derivative, also $0). Total instruments awarded on the date equal 1,110,850 shares. These were grants under the Tenaya Therapeutics, Inc. 2021 Equity Incentive Plan and do not represent an open‑market purchase or sale.

Key Details

• Transaction date: 2026-02-03; Form filed: 2026-02-05 (filed two days after the transaction).
• Prices: both awards reported at $0.00 (typical for grants/awards—no cash paid at grant).
• Vesting: RSUs vest as to 1/8th on August 15, 2026, then 1/8th every six months thereafter (F1, F2). The option vests monthly at 1/48th beginning one month after the grant date (F4).
• Additional note (F3): the filing references 369,875 shares that will be issued upon vesting of restricted stock units.
• Shares owned after the transaction: not specified in the provided filing excerpt.
• Timeliness: filing appears timely (filed two days after the transaction).

Context

• These are grants/awards (A) — not purchases or sales — so they do not signal immediate buying or selling of stock. Value is realized only if/when awards vest and, for options, if exercised. Vesting schedules stagger future potential dilution and align incentives over time.